Around the Web

Cancer News

Brachytherapy is an efficient treatment for numerous cancer diseases. To support this, the Cancer News regularly inform about related studies and articles as well as cancer demographics. Subscribe to our newsletter to receive the latest news first:
Subscription Cancer News
* Mandatory fields

Cancer News Around the Web

August 22, 2018

Long-term outcomes analysis of low-dose-rate brachytherapy in clinically T3 high-risk prostate cancer

Purpose: The available data demonstrating that superiority of LDR brachytherapy (LDR-BT) boost in high-risk prostate cancer patients under represents patients with extracapsular extension (T3a) and/or seminal vesicle invasion (T3b) have been limited. We report long-term clinical outcomes data for patients with cT3a/b disease receiving LDR-BT...

Read More

August 01, 2018

Cost-effectiveness of prostate boost with high-dose-rate brachytherapy versus intensity-modulated radiation therapy in the treatment of intermediate-high risk prostate cancer

PURPOSE: The recently published ASCENDE-RT randomized clinical trial demonstrated improved biochemical control, albeit with increased toxicity, for a prostate boost with brachytherapy versus external beam radiation therapy alone in patients with intermediate-high risk prostate cancer...

Read More

July 26, 2018

High-volume providers and brachytherapy practice: A Medicare provider utilization and payment analysis

PURPOSE: Brachytherapy is an important component of the treatment of gynecologic and prostate
cancers, with data supporting its impact on clinical outcomes. Prior data have suggested that brachytherapy tends to be focused at high-volume centers. Medicare reimbursement data can provide an understanding of the distribution of brachytherapy cases among billing providers...

Read More

July 18, 2018

High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localized prostate cancer: Toxicity and 6-year biochemical results

Purpose: To evaluate acute and late genitourinary toxicity, the gastrointestinal toxicity, and the long-term biochemical control after high-dose-rate (HDR) monotherapy in one fraction (20.5 Gy)...

Read More

June 30, 2018

Hypofractionated external beam radiation therapy in combination with HDR boost for localized prostate cancer: patient reported quality of life outcomes

Purpose: There is limited data to support the use of hypofractionated external beam radiation (HypoF) in combination with high-dose-rate brachytherapy (HDR). We report our quality of life (QOL) outcomes when treating intermediate and high-risk prostate cancer patients with external beam radiation (EBRT) plus HDR...

Read More

June 30, 2018

UK & Ireland Prostate Brachytherapy Practice Survey 2014-2016

Purpose: To document the current prostate brachytherapy practice across the UK and Ireland and compare with previously published audit results...

Read More

June 30, 2018

Low-dose-rate brachytherapy for prostate cancer in renal transplant recipients

Purpose: Prostate cancer (PCa) is the most common malignancy among men and one of the most common neoplasms affecting renal transplant recipients (RTRs). The available treatments for localized PCa among the general population (GP), surgery and external beam radiotherapy, carry a risk of damage to the transplanted kidney, the ureters, and the bladder and therefore tend to be avoided by most groups...

Read More

June 22, 2018

Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival

Background: Investigating oncological outcomes in patients registered in the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS) in terms of biochemical relapse-free survival (bRFS) by the Phoenix and the newly developed J-POPS definitions, exploration of predictive factors for bRFS, and preliminary verification of pitfalls of prostate-specific antigen (PSA) failure definitions...

Read More

May 08, 2018

The role of salvage brachytherapy for local relapse after external beam radiotherapy for prostate cancer

Prostate cancer is the most prevalent cancer amongst men. For localized disease, there currently exist several reliable treatment modalities including surgery, radiotherapy and brachytherapy. Our growing understanding of this disease indicates that local control plays a very important role in prevention of subsequent dissemination...

Read More

April 30, 2018

A single institution analysis of low-dose-rate brachytherapy: 5-year reported survival and late toxicity outcomes

Purpose: Low-dose-rate (LDR) brachytherapy has been used in Australia since 1998 as curative treatment, either as a boost to external beam radiotherapy (EBRT) or monotherapy in the management of non-metastatic prostate cancer. More recently, the use of Iodine-125 for permanent LDR brachytherapy implants...

Read More

March 30, 2018

Radiation Therapy Research: A Global Analysis 2001-2015

Radiation therapy is a core modality of cancer treatment; however, concerns have been expressed regarding its underutilization and its lack of prioritization as a research domain relative to other cancer treatment modalities, despite its rapid technical evolution...

Read More

March 27, 2018

Prostate segmentation in transrectal ultrasound using magnetic resonance imaging priors

Purpose: In the current standard of care, real-time transrectal ultrasound (TRUS) is commonly used for prostate brachytherapy guidance. As TRUS provides limited soft tissue contrast, segmenting the prostate gland in TRUS images is often challenging and subject to inter-observer and intra-observer variability, especially at the base and apex where the gland boundary is hard to define...

Read More

March 21, 2018

Prostate irradiation with focal dose escalation to the intraprostatic dominant nodule: a systematic review

Radiation therapy (RT) is a curative treatment option for localized prostate cancer. Prostate irradiation with focal dose escalation to the intraprostatic dominant nodule (IDN) is an emerging treatment option that involves the prophylactic irradiation of the whole prostate while increasing RT doses to the visible prostatic tumor...

Read More

March 06, 2018

Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer

Question: Is there a difference in prostate cancer–specific mortality and distant metastasis associated with extremely dose-escalated radiotherapy, external beam radiotherapy, or radical prostatectomy in patients with Gleason score 9-10 prostate cancer?

Read More

February 28, 2018

A comparative assessment of inhomogeneity and finite patient dimension effects in 60Co and 192Ir high-dose-rate brachytherapy

Purpose: To perform a comparative study of heterogeneities and finite patient dimension effects in 60Co and 192Ir high-dose-rate (HDR) brachytherapy...

Read More

February 20, 2018

NCCN releases updated guidelines on management of prostate cancer

As it does at least once a year, the National Comprehensive Cancer Network (NCCN) has just released version 1.2018 of its guidelines for physicians on the management of prostate cancer...

Read More

January 18, 2018

Quality of training in radiation oncology in Germany: where do we stand?

Purpose: To evaluate the current situation of young radiation oncologists in Germany with regard to the contents and quality of training and level of knowledge, as well as their working conditions and professional satisfaction...

Read More

January 01, 2018

Long-Term Prostate Specific Antigen Stability and Predictive Factors of Failure after Permanent Seed Prostate Brachytherapy

Defining biochemical failure as nadir + 2 may overestimate cure after radiotherapy. We assessed long-term prostate specific antigen stability after low dose rate prostate brachytherapy and predictors of biochemical failure when prostate specific...

Read More

December 12, 2017

Low dose rate prostate brachytherapy

Low dose rate (LDR) prostate brachytherapy is an evidence based radiation technique with excellent oncologic outcomes. By utilizing direct image guidance for radioactive source placement, LDR brachytherapy provides superior radiation dose escalation and conformality compared to external beam radiation therapy (EBRT)...

Read More

October 30, 2017

Does supplemental external beam radiation therapy impact urinary, bowel, and erectile function following permanent prostate brachytherapy?: results of two prospective randomized trials

Purpose: To evaluate the impact of supplemental external beam radiation therapy (EBRT) prior to permanent prostate brachytherapy on long term urinary, bowel, and erectile function...

Read More

October 30, 2017

Radiation treatment of prostate cancers – the contemporary role of modern brachytherapy techniques

Life expectancy is rising and the population is ageing in most countries [1]. Prostate cancer (PCa) is the second commonest diagnosed malignancy and it is the fifth leading cause of cancer mortality in men, representing a public health burden worldwide. Furthermore, the majority of PCa (around 62%) is diagnosed in men over 65 years [2]...

Read More

October 30, 2017

What pelvic radiation disease symptoms are experienced by patients receiving external beam radiotherapy and a high-dose-rate brachytherapy boost for prostate cancer?

Purpose: Research describing proctitis or pelvic radiation disease symptoms of prostate cancer patients one year after external beam radiotherapy (EBRT) plus high-dose-rate (HDR) brachytherapy is limited. This study aimed to assess prostate cancer patients’ pelvic radiation disease symptoms from baseline to 12 months post-radiotherapy...

Read More

August 30, 2017

Prostate cancer-specific death in brachytherapy treated high-risk patients stratified by pre-treatment PSA

Purpose: To evaluate prostate-cancer specific mortality (PCSM) in a cohort of high-risk patients treated with a permanent prostate brachytherapy approach, stratified by pre-treatment PSA...

Read More

August 30, 2017

Focal therapy for prostate cancer: the technical challenges

Focal therapy for prostate cancer has been proposed as an alternative treatment to whole gland therapy, offering the opportunity for tumor dose escalation and/or reduced toxicity. Brachytherapy, either low-dose-rate or high-dose-rate, provides an ideal approach, offering both precision in dose delivery and opportunity for a highly conformal, non-uniform dose distribution...

Read More

August 02, 2017

Long-term oncological outcomes and toxicity in 597 men aged ≤60 years at time of low-dose-rate brachytherapy for localised prostate cancer

Objectives: To report oncological and functional outcomes of men treated with low-dose-rate (LDR) prostate brachytherapy aged ≤60 years at time of treatment...

Read More

July 28, 2017

Brachytherapy patient safety events in an academic radiation medicine program

Purpose: To describe the incidence and type of brachytherapy patient safety events over 10 years in an academic brachytherapy program...

Read More

June 16, 2017

High-dose-rate brachytherapy as salvage modality for locally recurrent prostate cancer after definitive radiotherapy

Purpose: To review the current status of interstitial high-dose-rate brachytherapy as a salvage modality (sHDR BRT) for locally recurrent prostate cancer after definitive radiotherapy (RT)...

Read More

June 14, 2017

Long-term prognostic significance of rising PSA levels following radiotherapy for localized prostate cancer – focus on overall survival

Background: The aim of this study was to evaluate the long-term prognostic significance of rising PSA levels, particularly focussing on overall survival...

Read More

June 02, 2017

Patterns of Care Related to Post-Operative Radiotherapy for Patients with Prostate Cancer among Canadian Radiation Oncologists and Urologists

The American Society for Radiation Oncology (ASTRO) and American Urological Association (AUA) developed post-prostatectomy radiotherapy (RT) guidelines to aid patient counseling on adjuvant (ART) and salvage radiotherapy (SRT)...

Read More

May 15, 2017

Analysis of immune status after iodine-125 permanent brachytherapy in prostate cancer

Background: Permanent prostate brachytherapy (PPB) is an effective treatment choice for low and intermediate risk prostate cancer (PCa). However, the impact of PPB on tumor immune status is still poorly understood. This study aimed to assess the immune status in PCa patients before and at different time points after PPB (1, 3, 6, and 12 months)...

Read More

May 09, 2017

Second malignancies after permanent implant prostate cancer brachytherapy: A single-institution study of 675 patients treated between 1999 and 2003

Purpose: To analyse the rate of secondary malignancies observed in a series of 675 prostate cancer patients who underwent a permanent implant brachytherapy between 1999 and 2003, and to compare the incidence with the expected rate in a matched general French population...

Read More

April 28, 2017

Second salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer

Purpose: Local recurrent prostate cancer after primary radiotherapy is a significant clinical problem. Approximately, half of all patients with high-risk prostate cancer experience a recurrence within 10 years post treatment [1,2]...

Read More

April 28, 2017

Use of ultrasound in image-guided high-dose-rate brachytherapy: enumerations and arguments

Inherently, brachytherapy is the most conformal radiotherapeutic technique. As an aid to brachytherapy, ultrasonography (USG) serves as a portable, inexpensive, and simple to use method allowing for accurate, reproducible, and adaptive treatments...

Read More

April 23, 2017

Prostate brachytherapy, either alone or in combination with external beam radiation, is associated with longer overall survival in men with favorable pathologic Group 4 (Gleason score 8) prostate cancer

Purpose: Conventional prostate cancer risk stratification results in considerable heterogeneity within each prognostic group. Men with pathologic grade Group 4 (Gleason score 8) but otherwise low-risk features have been identified as a favorable subset of high-risk prostate cancer. Given recent randomized data supporting improved cancer outcome with brachytherapy...

Read More

April 19, 2017

Health-related quality of life outcomes from a contemporary prostate cancer registry in a large diverse population

Objective: To assess the health-related quality of life (HRQoL) of patients with prostate cancer up to 24 months after treatment in a contemporary large diverse population...

Read More

April 17, 2017

125I brachytherapy in younger prostate cancer patients

Purpose: To evaluate local recurrence in younger men treated with low-dose-rate (LDR) 125I brachytherapy (BT) for localized prostate cancer...

Read More

March 27, 2017

Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update

Purpose: To jointly update the Cancer Care Ontario guideline on brachytherapy for patients with prostate cancer to account for new evidence.

Methods: An Update Panel conducted a targeted systematic literature review and identified more recent randomized controlled trials comparing dose-escalated external beam radiation therapy (EBRT) with brachytherapy in men with prostate cancer...

Read More

February 28, 2017

High biologically effective dose radiation therapy using brachytherapy in combination with external beam radiotherapy for high-risk prostate cancer

High-risk prostate cancer is a category of prostate cancer that includes an aggressive tumor and/or a high tumor burden [1,2]. Importantly, inadequate local control in the management of the high-risk prostate cancer patients leads to metastasis or death...

Read More

January 06, 2017

US cancer death rate drops 25% since 1991

The cancer death rate in the United States has dropped 25 per cent from a peak in 1991, mainly due to a steady decline in smoking and advances in early detection and treatment of tumors, new research released Thursday shows...

Read More

December 30, 2016

Biochemical control and toxicity for favorable- and intermediate-risk patients using real-time intraoperative inverse optimization prostate seed implant: Less is more!

PURPOSE: To report the biochemical control rate and clinical outcomes with real-time inverse planning (inverse optimization prostate seed implant [IO-PSI]) for favorable-risk (FR) and intermediate-risk (IR) prostate adenocarcinoma in a community practice setting. This analysis is an extended followup of our initial report, with favorable early biochemical control rate (biochemical nonevidence of disease) of 97% at 4 years...

Read More

December 30, 2016

Comparative cost-effectiveness of focal and total salvage 125I brachytherapy for recurrent prostate cancer after primary radiotherapy

Purpose: Focal salvage (FS) iodine 125 (125I) brachytherapy could be an effective treatment for locally radiorecurrent prostate cancer (PCa). Toxicity is often reduced compared to total salvage (TS) while cancer control can be maintained, which could increase cost-effectiveness...

Read More

November 24, 2016

Comorbidity as a predictor of overall survival in prostate cancer patients treated with external beam radiotherapy combined with HDR brachytherapy boosts

Background: The risk stratification currently applied prior to curative treatment for localized prostate cancer (PC) does not take into account comorbidity or age. Therefore, we investigated the impact of comorbidity on overall survival (OS) in PC patients treated with external beam radiotherapy (EBRT) and high-dose rate (HDR) brachytherapy boost...

Read More

October 19, 2016

American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer

Purpose: To review outcomes for high-risk prostate cancer treated with combined modality radiation therapy (CMRT) utilizing external beam radiation therapy (EBRT) with a brachytherapy boost...

Read More

October 11, 2016

Prostate brachytherapy in Ghana: our initial experience

Purpose: This study presents the experience of a brachytherapy team in Ghana with a focus on technology transfer and outcome. The team was initially proctored by experienced physicians from Europe and South Africa...

Read More 

September 26, 2016

ASTRO 2016: Intermediate risk prostate cancer may be well controlled with brachytherapy alone

For men with intermediate risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects, when compared to more aggressive treatment that combines brachytherapy with external beam therapy (EBT)...

Read More

August 19, 2016

PSA Testing Advocates Earn Win with Medicare

For many of the thousands of American men who will be diagnosed with prostate cancer this year, the prostate-specific antigen test is the tool that will set off early alarm bells in their cases. This test, heavily under fire in recent years, just won a victory that advocates have been hoping for...

Read More

July 31, 2016

For very high-risk patients, EBRT + BT is superior to surgery or EBRT only

A retrospective analysis of oncological outcomes among modern-era patients with a Gleason score of 9 or 10 demonstrates a clear advantage to a combination of external beam radiation therapy (EBRT) with a brachytherapy (BT) boost to the prostate and short–term androgen deprivation therapy (ADT)...

Read More

June 29, 2016

Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer

Background and purpose: To estimate the risks of radiation-induced rectal and bladder cancers following low dose rate (LDR) and high dose rate (HDR) brachytherapy as monotherapy for localised prostate cancer and compare to external beam radiotherapy techniques...

Read More

June 27, 2016

Commissioning and Quality Control of the New Saginova HDR Treatment System; First Year Experience from the United Kingdom and Germany

Purpose: It is estimated that worldwide, less than one-quarter of centres undertake their own comprehensive local commissioning tests at installation of new HDR Brachytherapy equipment [1]. Commissioning and routine quality control (QC) of HDR brachytherapy treatment equipment is essential to avoid errors and assure quality...

Read More 

June 16, 2016

Long-term results of permanent implant prostate cancer brachytherapy: A single-institution study of 675 patients treated between 1999 and 2003

Purpose: To analyse long-term overall survival, relapse-free survival and late toxicities in a series of 675 patients treated between 1999 and 2003, with a median follow-up of 132 months...

Read More

Displaying results 51 to 100 out of 149

Search in Cancer News

GEC-ESTRO Handbook of Brachytherapy:


ABS Brachytherapy Guidelines and Consensus Statements: